Navidea Biopharmaceuticals plans to sell an $8 million milestone payment it has received and to seek a $2.75 million equity line of credit.
The radiopharmaceutical developer said these moves will provide funding for its phase IIb (NAV3-32) and phase III (NAV3-33) trials and expand operations.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
